Compare VRA & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | ABOS |
|---|---|---|
| Founded | 1982 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.6M | 165.6M |
| IPO Year | 2010 | 2021 |
| Metric | VRA | ABOS |
|---|---|---|
| Price | $7.53 | $0.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 474.4K | ★ 4.3M |
| Earning Date | 12-10-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.47 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $416,097,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.56 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $0.20 |
| 52 Week High | $7.13 | $3.60 |
| Indicator | VRA | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 81.50 | 20.64 |
| Support Level | $3.05 | N/A |
| Resistance Level | N/A | $2.68 |
| Average True Range (ATR) | 0.35 | 0.17 |
| MACD | 0.03 | -0.18 |
| Stochastic Oscillator | 90.97 | 1.57 |
Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.